Search Results - carlos+romo

1 Results

Sort By:

Targeted T-VEC immunotherapy for cutaneous neurofibromas

Value Proposition· Tumor-selective oncolysis: T‑VEC is an engineered oncolytic HSV‑1 that preferentially replicates in and lyses tumor cells, providing direct cytolytic reduction of cutaneous neurofibromas in preclinical models· Local, anti-tumor immune activation: preclinical evidence that tumor cell lysis and local GM-CSF expression promotes...

Published: 4/24/2026 | Inventor(s): Renyuan Bai, Verena Staedtke, Jaishri Blakeley, Carlos Romo

Keywords(s):

Category(s): Clinical and Disease Specializations > Genetic Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology